Breast cancer

Syllable Corporation Announces Purchase of Actium Health

Retrieved on: 
Wednesday, March 20, 2024
Data Management, Health, Technology, Health Technology, Software, General Health, Artificial Intelligence, Automation, Cardiovascular disease, Natural language processing, Growth, Learning, Communication, Intelligence, Partnership, Legacy Health, NewYork-Presbyterian Hospital, EMR, Patient, Risk, NLP, News, Prescription, AI, Nuvance Health, Virtua Health, Hospital, Breast cancer, Workforce, EHR, Partner, Oak, Nursing

Syllable, ( www.syllable.ai ), a leader in healthcare artificial intelligence and process automation, today announced its purchase of Actium Health.

Key Points: 
  • Syllable, ( www.syllable.ai ), a leader in healthcare artificial intelligence and process automation, today announced its purchase of Actium Health.
  • Together, Syllable and Actium Health provide AI-driven automation solutions that enable health systems to optimize patient volume/capacity, reduce staff burden, and deliver improved patient access and outcomes.
  • We look forward to learning how Syllable’s technology can help us further streamline our patient’s access to care working in conjunction with Actium Health.”
    Customers using Actium Health include: Virtua Health, Catholic Health System of Long Island, Nuvance Health, and Legacy Health.
  • Both Syllable and Actium Health have proven they can connect with patients at different moments in their healthcare journey, leading to improved experiences and health outcomes for the patients and maximum efficiency and revenue generation for health systems.”

Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Retrieved on: 
Wednesday, March 20, 2024
Research, General Health, Pharmaceutical, Oncology, Public Relations, Investor Relations, Clinical Trials, Science, Biotechnology, Communications, Practice Management, Other Science, Health, Fulvestrant, Carcinoma, Progression-free survival, Patient, JAMA Oncology, Pharming, Biomarker, CDK, Letrozole, IND, Triple-negative breast cancer, Puma Biotechnology, Cancer, Paclitaxel, Breast cancer, Anastrozole, Tamoxifen, FDA, Food, Pharmaceutical industry

This trial will investigate alisertib in combination with endocrine treatment (consisting of either anastrozole, exemestane, letrozole, fulvestrant or tamoxifen) in chemotherapy-naïve patients with hormone receptor-positive, HER2-negative recurrent or metastatic breast cancer.

Key Points: 
  • This trial will investigate alisertib in combination with endocrine treatment (consisting of either anastrozole, exemestane, letrozole, fulvestrant or tamoxifen) in chemotherapy-naïve patients with hormone receptor-positive, HER2-negative recurrent or metastatic breast cancer.
  • Puma plans to initiate this trial in the second half of 2024.
  • Patients must not have been previously treated with the endocrine treatment that will be given in combination with alisertib in the trial.
  • We look forward to the initiation of the ALISCA-Breast1 trial in the second half of 2024.”
    Alan H. Auerbach, Chief Executive Officer and President of Puma Biotechnology, said, “We are excited to move forward with the development of alisertib in HER2-negative hormone receptor-positive metastatic breast cancer.

Cotchett, Pitre & McCarthy Files Lawsuit on Behalf of Residents of Maywood, CA, for Exposure to Cancer Causing Ethylene Oxide

Retrieved on: 
Monday, March 18, 2024
Professional Services, Legal, Environment, Bone marrow, Public health, Inhalation, National Cancer Institute, Breast, Ethylene oxide, Cancer, Leukemia, Ethylene, Aplastic anemia, Complaint, Atmosphere, Breast cancer, Partner, Superior court, Family, Stomach, Spice, Los Angeles Times, Lymphoma, Stomach cancer, Oil

Cotchett, Pitre & McCarthy LLP filed a lawsuit on behalf of many longtime residents of Maywood, CA, next to Vernon, an industrial area, for their decades long exposure to cancer caused by carcinogenic Ethylene Oxide being released into the air.

Key Points: 
  • Cotchett, Pitre & McCarthy LLP filed a lawsuit on behalf of many longtime residents of Maywood, CA, next to Vernon, an industrial area, for their decades long exposure to cancer caused by carcinogenic Ethylene Oxide being released into the air.
  • Ethylene Oxide is used to sterilize medical equipment and spices but, during the process, some of the Ethylene Oxide escapes the facility into the surrounding air.
  • Ethylene Oxide is odorless and colorless, so nearby Maywood residents never knew it was in the air surrounding their homes.
  • According to the National Cancer Institute, and other protective health agencies around the world, Ethylene Oxide is associated with breast cancer, stomach cancer, lymphoma, and leukemia.

Avenacy Announces New Product Launches and Participation in DCAT Week 2024

Retrieved on: 
Monday, March 18, 2024
Biotechnology, General Health, FDA, Health, Pharmaceutical, HER2, Combination therapy, Fulvestrant, Growth, AstraZeneca, Entrepreneurship, DCAT, Merck, Merck & Co., Woman, Syringe, Breast cancer, Safety, Multimedia, Food, Injection, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240318415023/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240318415023/en/
    “Avenacy has had a strong start to 2024, with two product launches already executed and two more newly announced additions to our rapidly expanding portfolio.
  • Avenacy will begin shipping Fosaprepitant for Injection and Fulvestrant Injection to wholesale partners this week.
  • To learn more about Avenacy’s products or the Company’s exciting growth plans for 2024, please see the Avenacy management team at DCAT Week 2024 taking place in New York City from March 18-21st.
  • To request a meeting with a member of the Avenacy team, please reach out to [email protected] .

United States Cancer Contrast Media (Gadolinium, Iodinated) Market Size, Share & Trends Analysis Report 2024-2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 15, 2024
Health, Oncology, Diagnosis, Breast cancer, Gadolinium, Medicine, MRI, Growth, Prevalence, Agent handling, Patient, Public, Private sector, GE HealthCare, Google Images, Lung cancer, Investment, Smoking, Contrast (vision), Air pollution, USD, Government, Iodine, Medical imaging

The "U.S. Cancer Contrast Media Market Size, Share & Trends Analysis Report by Type (Gadolinium-based Contrast Media, Iodinated Contrast Media), Modality (Nuclear Imaging, CT scans), Application (Breast Cancer, Lung Cancer), and Segment Forecasts, 2024-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "U.S. Cancer Contrast Media Market Size, Share & Trends Analysis Report by Type (Gadolinium-based Contrast Media, Iodinated Contrast Media), Modality (Nuclear Imaging, CT scans), Application (Breast Cancer, Lung Cancer), and Segment Forecasts, 2024-2030" report has been added to ResearchAndMarkets.com's offering.
  • The U.S. cancer contrast media market is anticipated to reach USD 1.53 billion by 2030 and is anticipated to expand at a CAGR of 11.7% from 2024 to 2030.
  • Thus, these factors collectively propel the growth of U.S. cancer contrast media market.
  • Iodinated contrast media dominated the type segment with a share of 39.5% in 2023 owing to the increasing medical imaging procedures.

QT Imaging’s Breast Acoustic CT™ Scanner Used in Study for Early Identification of Response of Breast Cancer Patients to Neoadjuvant Chemotherapy

Retrieved on: 
Thursday, March 14, 2024
Research, Medical Devices, Women, Engineering, Manufacturing, Radiology, Consumer, Health, Science, Oncology, ACT, NAC, Partnership, Patient, Champaign–Urbana metropolitan area, Sunnybrook Health Sciences Centre, Biomarker, University of Illinois Urbana-Champaign, Cancer, University, Doctor of Philosophy, Electricity, MD, Computer engineering, Risk, Woman, Breast cancer, Safety, Radiation, Bangladesh Technical Education Board, Radiation therapy, Grainger College of Engineering, Medical imaging

This collaboration is part of a five-year research grant from National Institutes of Health/National Cancer Institute to develop an inexpensive, portable, safe, and repeatable imaging approach capable of accurate and early identification of response of breast cancer patients to neoadjuvant chemotherapy (NAC).

Key Points: 
  • This collaboration is part of a five-year research grant from National Institutes of Health/National Cancer Institute to develop an inexpensive, portable, safe, and repeatable imaging approach capable of accurate and early identification of response of breast cancer patients to neoadjuvant chemotherapy (NAC).
  • As part of this grant, Breast Acoustic CT™ (ACT) quantitative images with independent biomarkers known to be sensitive to cancer will be collected, and the response of cancer to therapy, will be derived from quantitative ultrasound based on backscatter analysis.
  • This collaboration also addresses the ongoing clinical need in breast cancer therapy for the development of an inexpensive, robust, and accurate technique to identify the response, within weeks, of breast cancer to neoadjuvant chemotherapy.
  • The early identification of non-responders to NAC or any cancer treatment remains a highly significant medical problem and necessary for adaptive precision medicine.

City of Hope to Present New Research at the American Association of Cancer Research (AACR) Annual Meeting 2024, Highlighting Promising Data on Prostate, Colorectal and Pancreatic Cancer

Retrieved on: 
Tuesday, March 12, 2024
Research, Other Health, General Health, Pharmaceutical, Oncology, Biometrics, Hospitals, Genetics, Health Technology, Science, Biotechnology, Health, Other Science, Breast cancer, Syngenic, Convergent, Computational biology, Patient, Distinguishing, Beckman Research Institute, City, Tumor microenvironment, PSCA, Haematopoietic system, Memory, AACR, Lymphocyte, Treatment, Convergent Science, Neoplasm, Road, Systems biology, CRC, Division, Microbiome, Hematology, Pharmaceutical industry

To investigate why Hispanic/Latino colorectal cancer (CRC) patients in Los Angeles face mortality rates up to 20% higher than their Caucasian counterparts, City of Hope’s Enrique Velazquez Villarreal, M.D., Ph.D., M.P.H., M.S.

Key Points: 
  • To investigate why Hispanic/Latino colorectal cancer (CRC) patients in Los Angeles face mortality rates up to 20% higher than their Caucasian counterparts, City of Hope’s Enrique Velazquez Villarreal, M.D., Ph.D., M.P.H., M.S.
  • They found that the model was sensitive to microbiome modulation and that the use of patient-derived human fecal matter transfers can significantly impact PSCA-CAR T cell directed anti-tumor responses.
  • , will also chair the inaugural AACR event called From Cancer Discoveries to Patients on April 4 and 5.
  • The event brings together leaders in clinical research, biotech and the investment community as part of AACR’s commitment to expediting the advancement of lifesaving cancer discoveries.

Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers

Retrieved on: 
Tuesday, March 12, 2024
Research, Women, Genetics, Clinical Trials, Biotechnology, Health, Consumer, Science, Oncology, Ovarian cancer, Patient, DNA, SGO, MD, Abstract, NTRA, Breast cancer, MRD, Gynecologic Oncology (journal), Medicare, Society of Gynecologic Oncology, Birth control

A total of seven abstracts will be presented, including two oral presentations and five poster presentations.

Key Points: 
  • A total of seven abstracts will be presented, including two oral presentations and five poster presentations.
  • The presentations will feature new data highlighting Signatera’s predictive and prognostic utility in ovarian cancer and other gynecologic malignancies.
  • “On the heels of receiving Medicare coverage for Signatera in ovarian cancer and for breast cancer in the neoadjuvant setting, we are thrilled to share new Signatera and Empower data with the gynecologic oncology community,” said Adam ElNaggar, MD, medical director of oncology at Natera.
  • “We believe this momentum is indicative of the growing clinical value our tests provide for patients across the continuum of gynecologic cancer care, and demonstrate our continued leadership in MRD.”
    Below is the full list of Signatera and Empower data presentations at the SGO Annual Meeting.

National Cancer Center Names Michelle Stack CEO Following Retirement of Long-Time Leader Regina English

Retrieved on: 
Wednesday, March 13, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Diagnosis, DNA repair, Brain, Beauty, Education, Research, DNA, Cancer, Prostate cancer, National Cancer Center, Breast cancer, Melanoma, Therapy, NCC, Management

The Board of National Cancer Center is pleased to announce that Michelle Stack has joined as CEO.

Key Points: 
  • The Board of National Cancer Center is pleased to announce that Michelle Stack has joined as CEO.
  • Ms. Stack replaces long-time leader Regina English , who is now Executive Director Emerita and Board member-at-large.
  • “We are delighted to name Michelle as CEO of National Cancer Center,” said Barry Peek , President of the Board.
  • NCC runs six cancer research programs: Aggressive Cancer Project; Fighting Childhood Leukemia; The Breast Cancer Project; Children’s Cancer Project; Prostate Cancer Project and the NCC Project, which funds research showing particular promise in the following areas: brain tumors, melanoma, DNA repair, anti-cancer therapies, gene mutations and targeted therapeutics for breast cancer.

As Opill Enhances Women's Reproductive Choices Dr. Mary Jane Minkin Highlights Key Differences Between the Progesterone-Only Opill and Traditional Estrogen-Based Contraceptives “The Pill”

Retrieved on: 
Monday, March 11, 2024
Health, FDA, Consumer, Women, Baby, Maternity, General Health, Pharmaceutical, Mother, Birth, Education, OBGYN, Combined oral contraceptive pill, Condom, Risk, Diabetes, Ovulation, Stroke, History, Sale, News, Fertility, Splenic infarction, Smoke, Perrigo, Woman, OTC, Pill, Cancer, Breast cancer, Safety, Progesterone, MUST, Migraine, Birth control

Progesterone-only pills or “mini pills’ are usually used for nursing mothers and those unable to take estrogen-based contraceptives for health reasons and individual medical history.

Key Points: 
  • Progesterone-only pills or “mini pills’ are usually used for nursing mothers and those unable to take estrogen-based contraceptives for health reasons and individual medical history.
  • "Education is key at this juncture to prevent an increase in unintended pregnancies in the coming months.
  • The Opill, significantly differs from the traditional birth control pill in that it is less effective at preventing ovulation when pills are missed or skipped for any reason.
  • The availability of the Opill OTC, or progesterone-only pill, is wonderful news for those women unable to take estrogen or 'The Pill.'